1
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

FDA's Treatment IND: Good News or Bad News for Cancer Care?

(Managing Editor)
Pages 24-27 | Published online: 19 Oct 2017
 

Summary:

Many providers believe the FDA's new “fast track” approval process for experimental drugs—treatment IND—is a step in the right direction, but participants at a recent AMA-FDA conference raised serious questions about such issues as payment, access, liability, and the effect on clinical trials.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.